Heartflow starts proving it is more than FFRCT
- Heartflow is a commercial AI medtech company built around the CCTA plus Heartflow pathway for coronary artery disease.
- Most revenue comes from pay-per-click fees when doctors order and review a Heartflow analysis.
- FFRCT Analysis remains the core product, but Plaque Analysis is gaining share and contributed strongly in Q2 2026.
- The platform story depends on Plaque Analysis, Plaque Staging, PCI Navigator, and the planned 2027 Plaque Tracker launch.
- The company lost $116.8 million in 2025 and had a $1.1 billion accumulated deficit at year-end.
A focused bet on heart CT
Heartflow wants to make coronary artery disease easier to diagnose without putting a tube into the heart. Doctors start with a coronary CT angiography scan, often called CCTA. Heartflow then uses software and AI to help show blood flow, narrowings, and plaque in the heart arteries.
The bull case centers on the company's high-margin software model and a massive market expansion opportunity. In late 2026 and early 2027, the company is starting three clinical trials to test its products on asymptomatic patients. Success there could add $6 billion to its U.S. total addressable market.
The bear case highlights severe unprofitability and structural vulnerability to changes in reimbursement rates. Heartflow carried a $1.1 billion accumulated deficit as of December 2025, and it faces an ongoing Civil Investigative Demand that management expects will take years to resolve.
The critical test over the next year is product diversification. Investors need proof that Plaque Analysis, Plaque Staging, and PCI Navigator can add real usage. Early signs are positive, with Plaque Analysis beating expectations in Q2 2026.
Paid each time doctors click
Heartflow makes money mainly on a usage model. Each time a physician chooses to review Heartflow FFRCT Analysis, Plaque Analysis, or both, the company recognizes a fee when it delivers the requested analysis.
This can be a strong model if volumes rise. Software revenue can scale without building a factory for each new case. Hospitals and imaging centers also do not need to buy a large device from Heartflow to start using the service.
The weak point is payment. Heartflow depends on reimbursement, which means insurers, Medicare coding rules, and hospital billing policies matter a lot. A lower rate, slower approvals, or confusing coverage could hurt usage even if the technology works.
The other weak point is adoption. Doctors must trust the workflow and change how they manage chest pain and coronary artery disease. New clinical guidelines can help, but they do not force every doctor to change quickly.
From one engine to a platform
Heartflow FFRCT Analysis
This is the commercial foundation. It estimates blood flow from a CCTA scan and helps doctors see whether a narrowing is likely to matter.
Heartflow Plaque Analysis
This product assesses coronary plaque. It showed strong commercial traction in Q2 2026, contributing meaningful U.S. revenue.
Heartflow Plaque Staging
Launched in July 2026, this tool helps with patient risk stratification based on clinical evidence.
Heartflow RoadMap Analysis
RoadMap is a workflow visualization tool. It supports the platform but is not a standalone growth engine in the current thesis.
Heartflow PCI Navigator
PCI Navigator launched in April 2026. It is meant to help plan revascularization, which means opening or bypassing blocked heart arteries.
Plaque Tracker
Plaque Tracker is expected in 2027. It would compare later CCTA scans with earlier scans to see whether plaque is getting better or worse over time.
Plaque starts to take share
While historically concentrated in FFRCT, Heartflow reported that Plaque Analysis contributed $7.8 million of its $59.6 million in U.S. revenue in Q2 2026.
What could break the story
Single-product dependence
High impact · High oddsFFRCT Analysis made up 98% of total cumulative revenue as of March 31, 2026. While Plaque Analysis is growing, the company is still exposed to one main workflow and one main payment path. If FFRCT growth slows, the platform thesis weakens fast.
Reimbursement pressure
High impact · Medium oddsHeartflow depends on third-party payment rates and coding policies. If Medicare, private insurers, or hospital billing rules become less favorable, doctors may order fewer analyses. A pay-per-click model works best only when payment is clear and repeatable.
Regulatory and legal overhang
Medium impact · Medium oddsThe company faces ongoing IP litigation and an active Civil Investigative Demand. Management warned in August 2026 that the CID will likely take years to resolve. This introduces long-term regulatory uncertainty.
Slow doctor adoption
High impact · Medium oddsHeartflow needs doctors to use CCTA plus Heartflow as part of their normal coronary artery disease workflow. Clinical evidence and guidelines may help, but practice patterns can change slowly. If hospitals do not train teams or change ordering habits, product launches may not become revenue.
Losses keep funding risk alive
High impact · Medium oddsHeartflow lost $116.8 million in fiscal 2025. It also had an accumulated deficit of $1.1 billion as of December 31, 2025. If losses stay large while growth slows, the company may need more capital on terms that hurt shareholders.
In one breath
What does Heartflow actually sell?
Heartflow sells cloud-based software analyses for coronary artery disease. A doctor orders an analysis after a CCTA heart scan, and Heartflow returns information about blood flow, plaque, and treatment planning.
Why is FFRCT so important for HTFL?
FFRCT Analysis is the product that built the business. It represented 98% of total cumulative revenue as of March 31, 2026, so growth and payment for that product still drive the company, even as new products launch.
What is the biggest thing to watch over the next year?
Watch whether Plaque Analysis, Plaque Staging, and PCI Navigator gain real use. The Q2 2026 results showed early success, which helps prove the multi-product platform story.
Is Heartflow profitable?
No. The company reported a $116.8 million net loss for fiscal 2025 and an accumulated deficit of $1.1 billion at December 31, 2025.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 23, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
